# Potential therapeutic targets for Membranous Nephropathy: proteome-wide Mendelian randomization and colocalization analysis

Zhihang Su[a1], Qijun Wan[a2*]

[a] Department of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, China

[*]Corresponding author: Qijun Wan (Email: yiyuan2224@sina.com)

Word Count:

Abstract: 334 words

Text (excluding references):   3507 words

Abstract

Background:

The currently available medications for treating membranous nephropathy (MN) still have unsatisfactory efficacy in inhibiting disease recurrence, slowing down its progression, and even halting the development of end-stage renal disease. There is still a need to develop novel drugs targeting MN.

Methods:

We utilized summary statistics of MN from the Kiryluk Lab and obtained data on 1699 plasma proteins from recently published genome-wide association studies. We performed a two-sample Mendelian randomization analysis and employed Steiger filtering for reverse causal relationship detection, Bayesian colocalization, phenotype scanning, and protein-protein interaction network.

Results:

The Mendelian randomization analysis uncovered 60 distinct proteins associated with MN. Proteins associated with an increased risk of MN in plasma include VWF [(Von Willebrand Factor) (WR OR = 1.412, 95%CI：1.157-1.725, P=0.0007)], TLL1 [ (Tolloid-Like Protein 1) (WR OR = 1.353, 95%CI：1.033-1.773, P=0.028, PPH4 = 0.986) ], REG3G[ (Regenerating Family Member 3 Gamma) (WR OR = 1.353, 95%CI：1.033-1.773, P=0.047, PPH4 = 0.542)], PROC [(Vitamin K-Dependent Protein C) (WR OR = 1.203, 95%CI：1.023-1.407, P=0.021)] and NCAM1[(Neural Cell Adhesion Molecule 1) (IVW OR = 1.391, 95%CI：1.019-1.899, P=0.037)], etc.. In contrast, proteins with protective effects against MN include CD27 [(Cd27 Antigen) ( WR OR = 0.785, 95%CI：0.681-0.904, P=0.0008)] and HRG[(Histidine-Rich Glycoprotein)(WR OR = 0.839, 95%CI：0.757-0.930, P=0.0008)], etc. After False Discovery Rate multiple correction, CD27 (P= 0.031), VWF (P= 0.031) and HRG (P= 0.031) still remain significant. None of these proteins exhibited a reverse causal relationship. Bayesian colocalization analysis provided evidence that TLL1 and REG3G share variants with MN. We found the interaction between CD27, NCAM1, PROC, and the target protein (CD20) of the targeted drug rituximab in MN.

Conclusions:

Our comprehensive analysis indicates a causal effect of CD27, VWF, HRG, TLL1, REG3G, NCAM1, and PROC at the genetically determined circulating levels on the risk of MN. NCAM1 has been confirmed as a pathogenic antigen in MN. These proteins have the potential to be a promising therapeutic target for the treatment of MN, warranting further clinical research.

Keywords: Membranous nephropathy; Mendelian randomization; Plasma Protein; Therapeutic targets

Introduction

Membranous Nephropathy (MN) is a common chronic autoimmune disease. MN may occur in both sexes and all ethnic groups. It is widely acknowledged that MN is the most common cause of adult nephrotic syndrome.(1) The prognosis of MN is challenging to predict, as some patients may experience spontaneous remission while others progress to end-stage renal disease.(2) Current mainstream treatments for MN include cyclophosphamide, glucocorticoids, rituximab, and calcineurin inhibitors.(3) In contrast to newly developed therapies targeting BAFF, plasma cells, and complement,(4) human circulating proteins play a crucial role in various biological processes and serve as primary drug targets.(5) The relevant literature has shown that protein drug targets with genetic associations supporting their connection to diseases are more likely to become drug targets and gain market recognition compared to targets discovered by chance.(6,7) In recent times, the application of Mendelian randomization (MR) analysis has gained significant traction in identifying potential therapeutic targets and repurposing drugs.(8) As an approach within genetic instrumental variable analysis, MR employs single nucleotide polymorphisms (SNPs) as instrumental variables (IVs) to estimate the causal relationship between exposures and outcomes.(9) Compared to traditional observational studies, MR has the ability to mitigate the impacts of type I errors and confounding factors.(10) As a result of advancements in large-scale genomic and proteomic technologies, the utilization of MR-based strategies has enabled the discovery of promising targets for therapeutic interventions in a variety of disorders, including Heart Failure,(11) multiple sclerosis,(12) and inflammatory bowel disease.(13) However, no MR study reports have integrated GWAS of MN and protein quantitative trait loci (pQTL) data to date. In the present investigation, our focus was to

ascertain plasma as a viable candidate for therapeutic intervention in the case of MN.

Figure 1 depicts the study design. Initially, we utilized MN data from Kiryluk Lab and plasma pQTL data to discern plausible causal plasma proteins associated with MN.(14) Next, we further validated the initial findings using Steiger filtering, Bayesian colocalization analysis, and phenoscanner. In a subsequent step, we constructed an interaction network linking potential protein targets with MN drug targets. Lastly, for reinforcement of our conclusions, we also conducted external validation Bayesian colocalization analysis using plasma pQTL data from a recently published study.(15)

Methods

plasma protein quantitative trait loci

We incorporated pQTLs that fulfilled the subsequent set of criteria: ①demonstrating a significant correlation at the genome-wide level (P < 5e-8)；② being situated outside the major histocompatibility complex (MHC) region (chr6, 26-34Mb)；③ demonstrate distinct associations [linkage disequilibrium (LD) clustering r^2 < 0.001]. In the preliminary analysis, we extracted plasma pQTL data from public research,(14) which consolidated findings from five public studies(16–20). With regard to the aforementioned selection criteria, a total of 2,113 cis and trans SNPs associated with 1,699 proteins were included. The aforementioned databases have been concurrently utilized in previous studies, alleviating concerns regarding their reliability.(12) Each database will be treated as an individual sample, and we will conduct MR on each of them. Plasma pQTL data of external validation was retrieved from a recent study,(16) which encompassed a cohort of 10,708 participants, enabling the quantification of a total of 4,775 plasma proteins. The above databases are all derived from European populations.

GWAS data of MN

Aggregate statistical data of MN, including individuals of European ancestry (Sample size of Cases=2150, Sample size of Control=5829, size of SNPs=5,327,688), were retrieved from the Kiryluk Lab.(21) All cases included in the final database were diagnosed as idiopathic membranous nephropathy using the gold standard method of renal biopsy. Furthermore, potential causes of secondary membranous nephropathy, such as medication, malignancies, infections, and autoimmune diseases, were systematically ruled out. Nonetheless, the study did not present a detailed description of the target antigens in the patients.

Mendelian randomization analysis

The Selection of Instrumental Variables

The IVs must meet the mentioned assumptions: relevance, exogeneity, and independence.

i. The IVs must exhibit a strong association with plasma protein. First, we selected SNPs falling beneath the locus-wide significance cutoff ($5 \times 10^{-8}$).

ii. The clumping processes were executed to maintain the IVs' independence and remove the linkage disequilibrium (LD) effect. Linkage disequilibrium ($r^2$) was set at 0.001, and genetic distance was set at 10,000 kb.

iii. $F = R2(n - k - 1)/ k (1 - R2)$, where R2 is the exposure variance calculated based on the data within the dataset. The number of IVs is k, and the samples are n. When F-statistic < 10, it indicates weak IVs, and they will be excluded.

Within this study, proteins were investigated as the primary variable of interest, representing the exposure, while MN served as the focal point of analysis, representing the outcome. The Wald ratio (WR) was utilized when it came to one SNP. (22) When two or more SNPs were accessible (the numbers of SNPs≥2), we utilized the inverse variance weighted (IVW) method, followed by

assessments of heterogeneity and horizontal pleiotropy.(23) In the process of conducting Mendelian

randomization (MR), in cases where effect allele frequency data is missing, we employ data from the

1000 Genomes project (HG19/GRCh37) as a substitute. The amplified risk of MN was indicated as

odds ratios (OR) per one-unit change in plasma protein levels, corresponding to a standard deviation

(SD) increase.

Reverse causality detection

In the presence of a sufficient number of SNPs, we will conduct a bidirectional MR analysis. If an

adequate number of SNPs is not available, we will resort to Stiger filtering as an alternative, which is

also a directional testing method.(24)

Bayesian colocalization analysis

Colocalization analysis was employed to evaluate the likelihood of two traits sharing a common

causal variant. As previously mentioned, the posterior probabilities of five hypotheses were utilized to

provide detailed supplementation to the results of colocalization analysis. Specifically, the first

hypothesis (PPH0) indicates "No association with either trait." The second hypothesis, posterior

probabilities of hypotheses (PPH1), represents, in this gene segment, there is only an association with

trait 1 but not with trait 2. Lastly, the third hypothesis (PPH2) signifies "Association with trait 2, but

not with trait 1." In our research, we assessed the posterior probabilities of hypotheses 3 and 4 (PPH3,

PPH4).(25) In hypothesis 3, exposure (plasma protein) and outcome (MN) are linked to the genomic

region through different SNPs, while in hypothesis 4, the protein and MN are both linked to the

genomic region through a shared SNP. By employing the coloc.abf algorithm, we defined genes as

having gene-based colocalization evidence when PPH4 > 80%.

Phenoscanner

We also employed Phenoscanner to uncover the connections of identified pQTLs with other traits. SNPs were classified as having horizontal pleiotropy when they exhibited connections with established risk factors for MN, encompassing metabolic traits, proteins, or clinical characteristics.

Protein-protein interaction network

In the plasma analysis, we investigated proteins potentially associated with MN. We primarily employed MR analysis with a significance level of P < 0.05 and directional tests. Furthermore, we explored the target proteins of drugs for MN available in the market. We identified these targeted drugs through a comprehensive review of the literature and by searching the DrugBank database (DrugBank | Powering health insights with structured drug data).(26,27) Additionally, we conducted a search for drugs targeting the potential pathogenic proteins we identified. Subsequently, protein-protein interaction (PPI) networks were employed to investigate the interplay among the proteins and the relevant targets. All PPI analyses were executed utilizing version 12.0 of the STRING database [STRING: functional protein association networks (string-db.org)],(28) with a predefined minimum threshold set at 0.5.

Results

Mendelian randomization analysis

Following the adherence to the principles of instrumental variable selection, a comprehensive set of 1335 IVs were included in the analysis. Employing a nominal significance threshold (P < 0.05), the MR analysis s identified 60 protein-MN associations. We discovered plasma proteins associated with an increased risk of MN: TLL1 [ (Tolloid-Like Protein 1) (WR OR = 1.353, 95%CI：1.033-1.773, P=0.028, PPH4 = 0.986) ], REG3G[ (Regenerating Family Member 3 Gamma) (WR OR = 1.353,

95%CI：1.033-1.773, P=0.047, PPH4 = 0.542)], PROC [(Vitamin K-Dependent Protein C) (WR OR = 1.203, 95%CI：1.023-1.407, P=0.021)] and NCAM1[(Neural Cell Adhesion Molecule 1) (IVW OR = 1.391, 95%CI :1.019-1.899, P=0.037)], etc. (Figure 2, Supplement Table S2 and Figure 1), and proteins that have a protective effect on MN: DSG2 [(Desmoglein-2) (IVW OR = 1.814, 95%CI：1.345-2.445, P=0.00009)], CD27 [(Cd27 Antigen) ( WR OR = 0.785, 95%CI：0.681-0.904, P=0.0008)], and VWF [(Von Willebrand Factor) (WR OR = 1.412, 95%CI：1.157-1.725, P=0.0007)], etc. (Figure 2 and Supplement Figure 1). After False Discovery Rate multiple correction, CD27 (P= 0.031), VWF (P= 0.031) and HRG (P= 0.031) still remain significant (Figure 3 and Supplement Table S1), and we should pay more attention to these proteins.

Sensitivity analysis and Reverse causality detection for MN causal proteins

The preliminary analysis did not detect any heterogeneity or horizontal pleiotropy in the analyzed proteins. Owing to the scarcity of IVs for plasma proteins (exposure) and their substantial correlation with the exposure, reverse MR was infeasible. Consequently, we resorted to directional testing to evaluate causality. Furthermore, Steiger filtering provided additional assurance regarding the presence of directional abnormalities. Steiger filtering consistently showed the correct directionality, and the significance level was P $<$ 0.05.

Bayesian co-localization analysis and Phenoscanner

Through colocalization analysis, TLL1 was identified as a potential drug target for MN among the 60 proteins analyzed in the MR analysis. Firstly, directional analysis failed to identify any causality of MN on protein levels of TLL1 (Supplement Table S2 and Figure 2). Secondly, strong Bayesian colocalization (PPH4 $>$ 0.8) and Moderate-strength Bayesian colocalization (0.5 $<$ PPH4 $<$ 0.8) indicated that TLL1 (PPH4=0.98) and REG3G (PPH4 = 0.54) shares the same variants with MN.

Finally, after phenoscanner, our findings revealed that TLL1 (rs6759924) is homologous to the *PLA2R1* gene, TLL1 (rs9271541) is homologous to the *TBC1D22B* gene, and REG3G (rs1634791) is homologous to the *HLA-B* gene (Figure 4 and Table 1). These proteins are not influenced by phenotypes related to IVs (Supplement Table S3).

The correlation among causal proteins and current drug targets for MN

The PPI network unveiled an interrelationship involving three proteins (NCAM1/PROC/ CD27) and an existing drug target for MN (CD20 targeted by rituximab). Using STRING, the identified reliable protein interaction axes include MS4A1-IGLL5/IGHV3-43-PROC, MS4A1-CD27-NCAM1, and MS4A1-NCAM1-CD27 (where NCAM1 has been previously confirmed as a pathogenic antigen for MN) (Supplement Figure 2). Therefore, we should pay more attention to the relationship between MS4A1 and NCAM1. For unknown proteins, CD27 is linked to the B lymphocyte antigen CD20 (MS4A1), which serves as the focus for rituximab, whereas PROC is linked to CD20 through protein-protein interactions with IGLL5/IGHV3. Furthermore, STRING analysis unveiled physical interactions between the aforementioned proteins and MS4A1, suggesting their close proximity without necessarily being in direct contact. The phenotype scan revealed that the aforementioned correlated proteins remained unaffected by other phenotypes, as all the phenotypes examined were unrelated to MN (Supplement Table S3).

Discussion

To our knowledge, this study represents the first attempt to integrate plasma proteomics data with MR and Bayesian colocalization approaches using many databases to investigate the potential involvement of specific proteins in MN. Lastly, we identified CD27, VWF, HRG, TLL1, REG3G,

PROC, and NCAM1 as potential drug targets for MN. Our research in proteomics holds significance, as proteins, acting as effectors in numerous biological processes,(29) are widely regarded as drug targets, unlike previous studies that primarily focus on single phenotypes or even precise dual-disease MR, which are typically gene-centric analyses susceptible to the influence of gene-gene and gene-environment interactions. Taking advantage of the rapid advancement in high-throughput sequencing, we integrated genome-wide association studies (GWAS) with proteomics, enabling the integration of genetic and protein-level information. By utilizing MR and employing a series of validation methods, we have newly identified several promising proteins, thereby augmenting their potential as targets for therapeutic interventions. Hence, in order to identify innovative targets for drug intervention in MN, we utilized a comprehensive analysis to evaluate the causal involvement of proteins in MN. Causal relationships identified through MR may include reverse causality, horizontal pleiotropy, or genetic confounding induced by linkage disequilibrium (LD). Therefore, in this study, we adhered to the three fundamental principles of instrumental variable selection in Mendelian randomization analysis. We utilized IVs that exhibited strong correlations with plasma proteins. We excluded IVs that demonstrated linkage disequilibrium during the implementation of MR. However, this limitation prevented us from conducting a reverse Mendelian randomization analysis. Subsequently, we performed Steiger filtering to exclude any potential reverse causality. We utilized cis and trans pQTLs as IVs as they are implicated in the regulation of gene expression at both the transcriptional and translational levels. Cis-pQTLs refer to variants located proximal to the gene encoding the protein under study, while trans-pQTLs represent distal regulatory elements that influence proteins through often unknown mechanisms.(30,31) Trans-pQTLs offer valuable insights into molecular connections in human biology. Additionally, Bayesian colocalization was employed to eliminate bias introduced by

LD.(32) Using a posterior probability threshold of 0.5, and we identified 60 proteins, including TLL1, CD27, PROC, and NCAM1, that may share the same MN variants. Nevertheless, these associations alone do not provide a complete explanation for the connection between the identified proteins and MN. To validate these findings, we examined the involvement of TLL1, which harbors an SNP (rs6759924) associated with the *PLA2R* gene (Table 1). This SNP is not linked to any phenotype, but its relationship with MN has not shown a significant impact thus far. The study also revealed the association between TLL1 and rs9271541 and between REG3G and rs1634791. The REG3G is encoded by gene *HLA-B*, which is located on the sixth chromosome in proximity to *HLA-D*. *HLA-D* encodes HLA class II antigens, known for their significant association with membranous nephropathy.(33) Fortunately, Phenoscanner analysis unveiled associations of the IVs for these four proteins with various phenotypes such as smoking, APTT, and thrombosis. These diverse phenotype associations are unrelated to MN, making it unlikely that the results are biased. Therefore, CD27, VWF, HRG, TLL1, REG3G, PROC, and NCAM1 may serve as potential drug targets for MN, with particular emphasis on CD27, VWF, HRG, TLL1, and REG3G. We also conducted network and database searches for targeted drugs against CD27, such as MK-5890 (monoclonal antibody),(34) Varlilumab (monoclonal antibody),(35), and CDX-527 (bispecific antibody).(36) These drugs hold promise as novel targeted therapies for the treatment of MN.

CD27 functions as a receptor for CD70/CD27L and may play a crucial role in the survival of activated T-cells. The MR result suggests that for every one standard deviation increase in circulating levels of CD27, there is a 0.784% decrease in the risk of MN. It is implicated in cellular apoptosis through its interaction with SIVA1.(37) CD27 exhibits protein-protein interactions with CD20 and NCAM1. While CD20-targeted therapy, rituximab, has become the mainstream treatment for MN. The

combination of PPI network analysis and MR revealed that therapeutic agents targeting CD27 have exhibited promising progress and evaluation in clinical trials, in contrast to the other identified targets in our study. Currently, targeted drugs against CD27, such as MK-5890 (monoclonal antibody), Varlilumab (monoclonal antibody), and CDX-527 (bispecific antibody), hold potential as new targeted therapies for the treatment of MN. Based on our research findings, we hypothesize that these antibodies may have an impact on MN, and therefore, we recommend future clinical studies to further investigate this hypothesis.

VWF, also known as Von Willebrand Factor. It plays a vital role in hemostasis and serves as a carrier for clotting factors. Upon blood vessel damage, a significant number of platelets adhere to collagen fibers, forming a clot, where VWF acts as a mediator in hemostasis. The binding of VWF factor to clotting factor VIII stabilizes and regulates its activity. After FDR correction, it still remains significant. The MR result suggests that for every one standard deviation increase in circulating levels of VWF, there is a 0.839% decrease in the risk of MN.

HRG, also known as Histidine-Rich Glycoprotein. Plasma glycoprotein can bind to various ligands, such as hemoglobin, acetylated hepari and plasminogen. After FDR correction, it still remains significant. The MR result suggests that for every one standard deviation increase in circulating levels of HRG, there is a 1.412% increase in the risk of MN.

TLL1, also known as Tolloid-Like Protein 1, is a protease that performs a vital function in the processing of procollagen C-propeptides. This includes substrates such as chordin, pro-biglycan, and pro-lysyl oxidase. It is essential for embryonic development and acts as a predominant protease, influencing dorsal-ventral patterning and skeletogenesis.(38,39) The MR result suggests that for every one standard deviation increase in circulating levels of TLL1, there is a 1.353% increase in the risk of

MN.

NCAM1, also known as Neural Cell Adhesion Molecule 1, is a cell adhesion molecule that plays a crucial role in neuron-neuron adhesion, neurite fasciculation, and neurite outgrowth, among other functions. It has been identified as a pathogenic antigen in MN, and in our study, its circulating levels were found to be protective. However, the relationship between the levels of circulating NCAM1 and MN renal disease remains unknown. Through our research, our findings also suggest that its circulating levels have a significant impact on MN at both the genetic and protein levels. This result suggests that for every one standard deviation increase in circulating levels of NCAM1, there is a 1.391% increase in the risk of MN. These findings are significant in terms of the serological testing for patients with MN, highlighting the need for future research to clarify the directionality of these associations.

REG3G is short for Regenerating Family Member 3 Gamma. We discovered that counteracting Gram-positive bacteria can be achieved through binding to the carbohydrate portion of peptidoglycan surfaces, leading to bacterial killing. This mechanism can restrict the activation of the microbiota in adaptive immune responses. The MR result suggests that for every one standard deviation increase in circulating levels of REG3G, there is a 0.817% decrease in the risk of MN. In the protein-protein interaction (PPI) network, we also identified associations with EGFR and the interleukin family. Several studies have suggested a potential link between this mechanism and liver cancer. It is speculated that this mechanism may impact membranous nephropathy through inflammation and cancer pathways; however, further research is required to validate this hypothesis.

PROC is an abbreviation for Vitamin K-dependent protein C heavy chain. Protein C is a vitamin K-dependent serine protease that regulates blood coagulation by inactivating factors Va and VIIIa in the presence of calcium ions and phospholipids.(40) It protects the endothelial cell barrier function and

belongs to the peptidase S1 family. The MR result suggests that for every one standard deviation increase in circulating levels of PROC, there is a 1.203% increase in the risk of MN. We also discovered its interaction with CD20 through IGLL5 or IGHV3-43.

In conclusion, we utilized proteomics and MR analysis to identify drug targets for MN. Unlike previous studies that focused solely on the genetic level, our analysis incorporated both genetic and protein levels. Considering the limited availability of targeted drugs for the treatment of MN, we have successfully identified several potential therapeutic targets that require further investigation in the future.

There are several limitations in our research. Firstly, the plasma protein data we utilized was obtained from a combination of multiple proteomic studies, which may employ varying standards for protein measurement. Nevertheless, we selected data that matched circulating protein data with GWAS. Secondly, most proteins are associated with only one SNP, indicating either a lack of trans-pQTL or cis-pQTL. The limited number of IVs hindered the application of MR techniques, such as heterogeneity tests, multilevel effects tests, and reverse MR analysis. To address this limitation, we employed Steiger filtering for directional tests and corroborated the results using other databases. Thirdly, the data we employed in our experiments exclusively represented European populations, necessitating further research to generalize the findings to other ethnicities. However, the pathogenic role of NCAM1, identified in our study, a homonymous protein (plasma protein) of a pathogenic antigen in MN, thereby increasing the feasibility of extending our research to the broader population and validating our MR result. Lastly, although we identified interactions between our causal proteins and CD20, which is targeted by rituximab, through the protein-protein interaction network, it does not imply that these causal proteins are therapeutic targets for MN. Additional research is warranted in this regard.

List of abbreviations

MN: Membranous nephropathy,

MR: Mendelian Randomization,

GWAS: genome-wide association studies,

SNPs: single nucleotide polymorphisms,

IVs: instrumental variables,

VWF: Von Willebrand Factor,

WR: Wald Ratio,

IVW: inverse variance weighted,

OR: Odds Ratio,

95%CI: Confidence Interval,

P: P-value,

TLL1: Tolloid-Like Protein 1,

PPH: posterior probabilities of hypotheses,

REG3G: Regenerating Family Member 3 Gamma,

PROC: Vitamin K-Dependent Protein C,

NCAM1: Neural Cell Adhesion Molecule 1,

CD27: Cd27 Antigen,

HRG: Histidine-Rich Glycoprotein.

# Declarations

Authors' contributions

The efforts were jointly accomplished by Zhihang Su and Qijun Wan.

Data availability

Plasma pQTL data was derived via public research.[Error! Bookmark not defined.,Error! Bookmark not defined.] MN data

was retrieved from Kiryluk Lab.(21) We used R language version 4.3.0 for our analysis. In R language,

we utilized the "coloc (https://github.com/chr1swallace/coloc.git)" and "TwoSampleMR

(https://github.com/MRCIEU/TwoSampleMR.git)" and "locuscompare" packages for our analysis.(41)

Ethics approval and consent to participate

Our data is publicly available, which is in accordance with ethical standards.

Role of the funding source

The study sponsor had no role in any part of our research.

Funding:

Shenzhen Key Medical Discipline Construction Fund (SZXK009).

Acknowledgments

Sincere thanks to all participants who participated in the production of the public database.

Data Sharing Statement

The datasets can be provided by the first author upon reasonable request.

Declaration of interests

No conflict of interest.

References:

1. Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol CJASN. 2017 Jun 7;12(6):983–97.

2. Scolari F, Dallera N, Gesualdo L, Santoro D, Pani A, Santostefano M, et al. Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial. BMJ Open. 2019 Dec 4;9(12):e029232.

3. Caravaca-Fontán F, Fernández-Juárez GM, Floege J, Goumenos D, Kronbichler A, Turkmen K, et al. The management of membranous nephropathy-an update. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2022 May 25;37(6):1033–42.

4. Lin YC, Gau TS, Jiang ZH, Chen KY, Tsai YT, Lin KY, et al. Targeted therapy in glomerular diseases. J Formos Med Assoc Taiwan Yi Zhi. 2023 Jul 11;S0929-6646(23)00248-6.

5. Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals - PubMed [Internet]. [cited 2023 Oct 4]. Available from: https://pubmed.ncbi.nlm.nih.gov/33067605/

6. Jhamb D, Magid-Slav M, Hurle MR, Agarwal P. Pathway analysis of GWAS loci identifies novel drug targets and repurposing opportunities. Drug Discov Today. 2019 Jun;24(6):1232–6.

7. King EA, Davis JW, Degner JF. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet. 2019 Dec;15(12):e1008489.

8. Reay WR, Cairns MJ. Advancing the use of genome-wide association studies for drug repurposing. Nat Rev Genet. 2021 Oct;22(10):658–71.

9. Bowden J, Holmes MV. Meta-analysis and Mendelian randomization: A review. Res Synth Methods. 2019 Dec;10(4):486–96.

10. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018 Jul 12;362:k601.

11. Henry A, Gordillo-Marañón M, Finan C, Schmidt AF, Ferreira JP, Karra R, et al. Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization. Circulation. 2022 Apr 19;145(16):1205–17.

12. Lin J, Zhou J, Xu Y. Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis. Brain J Neurol. 2023 Aug 1;146(8):3364–72.

13. Chen J, Xu F, Ruan X, Sun J, Zhang Y, Zhang H, et al. Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses. eBioMedicine [Internet]. 2023 Mar 1 [cited 2023 Aug 26];89. Available from: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(23)00059-2/fulltext

14. Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, et al. Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. Nat Genet. 2020 Oct;52(10):1122–31.

15. Pietzner M, Wheeler E, Carrasco-Zanini J, Cortes A, Koprulu M, Wörheide MA, et al. Mapping the proteo-genomic convergence of human diseases. Science. 2021 Nov 12;374(6569):eabj1541.

16. Genomic atlas of the human plasma proteome - PubMed [Internet]. [cited 2023 Oct 4]. Available from: https://pubmed.ncbi.nlm.nih.gov/29875488/

17. Suhre K, Arnold M, Bhagwat AM, Cotton RJ, Engelke R, Raffler J, et al. Connecting genetic risk to disease end points through the human blood plasma proteome. Nat Commun. 2017 Feb 27;8:14357.

18. Yao C, Chen G, Song C, Keefe J, Mendelson M, Huan T, et al. Genome-wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease. Nat Commun. 2018 Aug 15;9(1):3268.

19. Emilsson V, Ilkov M, Lamb JR, Finkel N, Gudmundsson EF, Pitts R, et al. Co-regulatory networks of human serum proteins link genetics to disease. Science. 2018 Aug 24;361(6404):769–73.

20. Folkersen L, Fauman E, Sabater-Lleal M, Strawbridge RJ, Frånberg M, Sennblad B, et al. Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease. PLoS Genet. 2017 Apr;13(4):e1006706.

21. Xie J, Liu L, Mladkova N, Li Y, Ren H, Wang W, et al. The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nat Commun. 2020 Mar 30;11(1):1600.

22. Chen D, Zhang Y, Yidilisi A, Xu Y, Dong Q, Jiang J. Causal Associations Between Circulating Adipokines and Cardiovascular Disease: A Mendelian Randomization Study. J Clin Endocrinol Metab. 2022 May 17;107(6):e2572–80.

23. Huang D, Lin S, He J, Wang Q, Zhan Y. Association between COVID-19 and telomere length: A bidirectional Mendelian randomization study. J Med Virol. 2022 Nov;94(11):5345–53.

24. Deng YT, Ou YN, Wu BS, Yang YX, Jiang Y, Huang YY, et al. Identifying causal genes for depression via integration of the proteome and transcriptome from brain and blood. Mol Psychiatry. 2022 Jun;27(6):2849–57.

25. Zuber V, Grinberg NF, Gill D, Manipur I, Slob EAW, Patel A, et al. Combining evidence from Mendelian randomization and colocalization: Review and comparison of approaches. Am J Hum Genet. 2022 May 5;109(5):767–82.

26. Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074–82.

27. Keri KC, Blumenthal S, Kulkarni V, Beck L, Chongkrairatanakul T. Primary membranous nephropathy: comprehensive review and historical perspective. Postgrad Med J. 2019 Jan;95(1119):23–31.

28. Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023 Jan 6;51(D1):D638–46.

29. Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease

risk and therapeutic targets - PubMed [Internet]. [cited 2023 Oct 4]. Available from: https://pubmed.ncbi.nlm.nih.gov/37563310/

30. Zhang J, Dutta D, Köttgen A, Tin A, Schlosser P, Grams ME, et al. Plasma proteome analyses in individuals of European and African ancestry identify cis-pQTLs and models for proteome-wide association studies. Nat Genet. 2022 May;54(5):593–602.

31. The genetic regulation of protein expression in cerebrospinal fluid - PubMed [Internet]. [cited 2023 Oct 4]. Available from: https://pubmed.ncbi.nlm.nih.gov/36504281/

32. Mitochondrial related genome-wide Mendelian randomization identifies putatively causal genes for multiple cancer types - PubMed [Internet]. [cited 2023 Oct 4]. Available from: https://pubmed.ncbi.nlm.nih.gov/36634566/

33. Ronco P, Beck L, Debiec H, Fervenza FC, Hou FF, Jha V, et al. Membranous nephropathy. Nat Rev Dis Primer. 2021 Sep 30;7(1):69.

34. Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy - PubMed [Internet]. [cited 2023 Oct 4]. Available from: https://pubmed.ncbi.nlm.nih.gov/36100308/

35. Burris HA, Infante JR, Ansell SM, Nemunaitis JJ, Weiss GR, Villalobos VM, et al. Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2017 Jun 20;35(18):2028–36.

36. Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy - PubMed [Internet]. [cited 2023 Oct 4]. Available from: https://pubmed.ncbi.nlm.nih.gov/32451681/

37. Prasad KV, Ao Z, Yoon Y, Wu MX, Rizk M, Jacquot S, et al. CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein. Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6346–51.

38. Bone morphogenetic protein-1: the type I procollagen C-proteinase - PubMed [Internet]. [cited 2023 Oct 4]. Available from: https://pubmed.ncbi.nlm.nih.gov/8553073/

39. Hopkins DR, Keles S, Greenspan DS. The bone morphogenetic protein 1/Tolloid-like metalloproteinases. Matrix Biol J Int Soc Matrix Biol. 2007 Sep;26(7):508–23.

40. Griffin JH, Fernández JA, Gale AJ, Mosnier LO. Activated protein C. J Thromb Haemost JTH. 2007 Jul;5 Suppl 1:73–80.

41. Liu B, Gloudemans MJ, Rao AS, Ingelsson E, Montgomery SB. Abundant associations with gene expression complicate GWAS follow-up. Nat Genet. 2019 May;51(5):768–9.

Figure Legends

Figure 1: Study design

Figure 2: Mendelian randomization and Steiger filtering result of causal plasma proteins

CI, confidence interval; OR, odds ratio; steiger_pval, P value of Steiger filtering result; correct_causal_direction, correct direction of causality; pval, P value of Mendelian randomization result; MN, membranous nephropathy

Figure 3: Detailed results of Mendelian randomization for positive proteins after False Discovery Rate multiple correction

The x-axis represents the OR (Odds Ratio) values, and the y-axis represents the -log10(p-value). The red dots represent plasma proteins that remain significant after FDR (False Discovery Rate) correction.

Figure 4: The results of co-localization analysis

Our findings identified TLL1 (rs6759924 and rs9271541) and REG3G (rs1634791) as having moderate and strong co-localization significance with membranous nephropathy. The figure displays meaningful co-localization results, with the instrumental variables and their chromosomal positions visualized.

Supplement Figure 1: Detailed results of Mendelian randomization for positive proteins

From outer to inner, the first circle represents the number of instrumental variables, the second circle represents the beta of the Mendelian randomization result, the third circle represents the standard deviation of the Mendelian randomization result, the fourth circle represents the P-value of the Mendelian randomization result, and the fifth circle represents the odds ratio (OR) of the Mendelian randomization result.

Supplement Figure 2: Protein-protein interaction

This picture shows the connection between protein interactions. We identified proteins associated with CD20 and performed clustering analysis to select hub proteins. CD27, PROC, and NCAM1 are all

present in this network. Each category is represented by the same color.

| Exposure: Plasma | | Wald Ratio | | 1. Reverse causality | | Current Membranous |
| 734 proteins with cis-pQTL. | | or | | 2. Bayesian colocalization | | Nephropathy drug targets |
| 986 proteins with trans-pQTL. | | Inverse Variance Weighted | | 3. Phenoscanner | | |
| Outcome: Membranous | | | | | | |
| Nephropathy | | | | | | |
| 2150 cases/5829 controls | | | | | | |

| Data Selection | | Mendelian Randomization Analysis | | Sensitivity Analysis | | Protein-protein Interaction |

| EXPOSURE ON OUTCOME(MN) | method | pval | | OR(95%CI) | steiger_pval | correct_causal_direction |
|---|---|---|---|---|---|---|
| LGALS3BP | Wald ratio | 0.015562638 | | 0.50 (0.28 – 0.88) | 2.27871e-04 | TRUE |
| AP1G2 | Wald ratio | 0.010782528 | | 0.56 (0.36 – 0.88) | 2.52000e-07 | TRUE |
| BCAN | Wald ratio | 0.043941927 | | 0.62 (0.39 – 0.99) | 2.04000e-06 | TRUE |
| FAM177A1 | Wald ratio | 0.020960476 | | 0.65 (0.46 – 0.94) | 4.82000e-20 | TRUE |
| ALPI | Wald ratio | 0.020960476 | | 0.66 (0.46 – 0.94) | 7.10000e-19 | TRUE |
| IL11RA | Wald ratio | 0.026349714 | | 0.67 (0.47 – 0.95) | 1.28000e-14 | TRUE |
| QPCT | Wald ratio | 0.010490078 | | 0.67 (0.49 – 0.91) | 1.71000e-15 | TRUE |
| TIMP4 | Wald ratio | 0.000612277 | | 0.67 (0.53 – 0.84) | 5.41000e-29 | TRUE |
| IL16 | Wald ratio | 0.002112862 | | 0.69 (0.55 – 0.88) | 1.73000e-33 | TRUE |
| TIMP2 | Wald ratio | 0.021999722 | | 0.70 (0.52 – 0.95) | 1.18000e-16 | TRUE |
| CHST15 | Wald ratio | 0.020960476 | | 0.72 (0.55 – 0.95) | 2.35000e-17 | TRUE |
| CD5L | Wald ratio | 0.042738867 | | 0.74 (0.56 – 0.99) | 1.45000e-23 | TRUE |
| IFI16 | Wald ratio | 0.015188596 | | 0.75 (0.60 – 0.95) | 5.65000e-29 | TRUE |
| PRDX6 | Wald ratio | 0.040184062 | | 0.76 (0.59 – 0.99) | 1.99000e-19 | TRUE |
| CD27 | Wald ratio | 0.000801510 | | 0.78 (0.68 – 0.90) | 1.34000e-35 | TRUE |
| LRPPRC | Wald ratio | 0.000801510 | | 0.79 (0.69 – 0.91) | 3.26000e-104 | TRUE |
| CTSC | Wald ratio | 0.004747406 | | 0.80 (0.69 – 0.93) | 3.38000e-67 | TRUE |
| REG3G | Wald ratio | 0.047273860 | | 0.82 (0.67 – 1.00) | 1.37000e-39 | TRUE |
| HTATIP2 | Wald ratio | 0.017024469 | | 0.84 (0.73 – 0.97) | 2.72000e-79 | TRUE |
| SPINK6 | Wald ratio | 0.010549955 | | 0.84 (0.74 – 0.96) | 1.32000e-86 | TRUE |
| HRG | Wald ratio | 0.000801510 | | 0.84 (0.76 – 0.93) | 2.94000e-80 | TRUE |
| EMC4 | Wald ratio | 0.033849760 | | 0.85 (0.73 – 0.99) | 2.96000e-89 | TRUE |
| MMP12 | Wald ratio | 0.043904649 | | 0.86 (0.74 – 1.00) | 2.88000e-72 | TRUE |
| ICAM5 | Inverse variance weighted | 0.023465542 | | 0.89 (0.81 – 0.98) | 1.15000e-172 | TRUE |
| FUT8 | Wald ratio | 0.017024469 | | 0.89 (0.82 – 0.98) | 6.07000e-135 | TRUE |
| ERAP2 | Wald ratio | 0.039033858 | | 1.09 (1.00 – 1.18) | 7.98000e-137 | TRUE |
| ABO | Wald ratio | 0.000806401 | | 1.12 (1.05 – 1.19) | 2.12000e-129 | TRUE |
| ACAP2 | Wald ratio | 0.000806401 | | 1.12 (1.05 – 1.19) | 2.12000e-129 | TRUE |
| ACBD6 | Wald ratio | 0.000806401 | | 1.12 (1.05 – 1.19) | 2.12000e-129 | TRUE |
| ACBD7 | Wald ratio | 0.000806401 | | 1.12 (1.05 – 1.19) | 2.12000e-129 | TRUE |
| CDH5 | Wald ratio | 0.028368976 | | 1.14 (1.01 – 1.28) | 9.86000e-102 | TRUE |
| GPC5 | Wald ratio | 0.016927148 | | 1.15 (1.02 – 1.28) | 6.36000e-135 | TRUE |
| DHX8 | Wald ratio | 0.008580811 | | 1.17 (1.04 – 1.31) | 1.50000e-133 | TRUE |
| FGF2 | Wald ratio | 0.020818593 | | 1.19 (1.03 – 1.39) | 1.06000e-31 | TRUE |
| CD209 | Wald ratio | 0.000806401 | | 1.19 (1.07 – 1.31) | 2.12000e-129 | TRUE |
| PROC | Wald ratio | 0.021054571 | | 1.20 (1.03 – 1.41) | 7.51000e-31 | TRUE |
| NQO1 | Wald ratio | 0.008333326 | | 1.20 (1.05 – 1.38) | 3.94000e-100 | TRUE |
| CLPS | Wald ratio | 0.009059171 | | 1.28 (1.06 – 1.55) | 8.53000e-43 | TRUE |
| CD36 | Wald ratio | 0.030890122 | | 1.30 (1.02 – 1.65) | 5.98000e-19 | TRUE |
| NUDT16L1 | Wald ratio | 0.048144929 | | 1.31 (1.00 – 1.70) | 3.26000e-22 | TRUE |
| LRRC15 | Wald ratio | 0.023755812 | | 1.31 (1.04 – 1.65) | 1.82000e-32 | TRUE |
| TLL1 | Wald ratio | 0.027866655 | | 1.35 (1.03 – 1.77) | 7.15000e-15 | TRUE |
| IL27RA | Wald ratio | 0.029085320 | | 1.37 (1.03 – 1.82) | 1.77000e-13 | TRUE |
| FAM151A | Wald ratio | 0.046003671 | | 1.38 (1.01 – 1.90) | 6.38000e-14 | TRUE |
| NCAM1 | Inverse variance weighted | 0.037409364 | | 1.39 (1.02 – 1.90) | 1.85000e-25 | TRUE |
| SEMA6A | Wald ratio | 0.029085320 | | 1.40 (1.04 – 1.91) | 1.56000e-11 | TRUE |
| VWF | Wald ratio | 0.000703439 | | 1.41 (1.16 – 1.72) | 1.13000e-14 | TRUE |
| RET | Wald ratio | 0.022866044 | | 1.54 (1.06 – 2.24) | 1.37000e-10 | TRUE |
| GFRAL | Inverse variance weighted | 0.003274007 | | 1.55 (1.16 – 2.07) | 1.06000e-12 | TRUE |
| HBEGF | Wald ratio | 0.042745269 | | 1.58 (1.02 – 2.46) | 3.11000e-07 | TRUE |
| BCAM | Wald ratio | 0.027866655 | | 1.60 (1.05 – 2.42) | 5.23000e-06 | TRUE |
| SEMA3C | Wald ratio | 0.033344797 | | 1.69 (1.04 – 2.73) | 1.59000e-06 | TRUE |
| GNPTG | Wald ratio | 0.019540380 | | 1.69 (1.09 – 2.63) | 3.96000e-07 | TRUE |
| ATP4B | Wald ratio | 0.027293855 | | 1.73 (1.06 – 2.83) | 2.96000e-06 | TRUE |
| TNFRSF1B | Wald ratio | 0.031584331 | | 1.74 (1.05 – 2.88) | 4.15000e-08 | TRUE |
| DSG2 | Inverse variance weighted | 0.000093500 | | 1.81 (1.35 – 2.45) | 1.81000e-12 | TRUE |
| TYMP | Wald ratio | 0.011980433 | | 1.88 (1.15 – 3.07) | 1.42000e-05 | TRUE |
| AFP | Wald ratio | 0.006635920 | | 2.01 (1.21 – 3.32) | 3.25548e-04 | TRUE |
| DHFR | Wald ratio | 0.000521739 | | 2.21 (1.41 – 3.47) | 5.80000e-05 | TRUE |
| CHST11 | Wald ratio | 0.000574457 | | 2.26 (1.42 – 3.60) | 1.24470e-04 | TRUE |

*Protective Circulating Protein for MN*

0.5 1 2 3

← Low risk    High risk →

# plasma protein MR result after FDR